Veru Inc (VERU) Stock Price, Quote & News

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to preven...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 509 6897

Website: verupharma.com

Address:

2916 North Miami Avenue, Suite 1000, Miami, United States

mrkymrk Aug. 2 at 2:03 PM

$VERU He is quite the Specker isn’t he?!

0 · Reply

NolAsrtormZ Aug. 2 at 1:20 PM

$VERU 5 business days for an 8k

0 · Reply

NolAsrtormZ Aug. 2 at 1:16 PM

$VERU they inform about a conference in November which is months AWAY But Wont inform investors of reverse split date and exact ratio which is Due in business days. Their priorities sheeeesh

0 · Reply

Woundntyouliketoknow Aug. 2 at 10:41 AM

$VERU Conference: Obesity, Metabolism & Weight Management Nov 19, 20 https://www.obesityconferences.com/speaker-details.php?speaker=3818#

1 · Reply

Eesnimi Aug. 2 at 3:45 AM

$VERU 1000% is not enough anymore to arrive to normality. Needs +1100%

0 · Reply

NolAsrtormZ Aug. 2 at 2:16 AM

$VERU NO 8k today. 5 business days until they must tell nasdaq a specific date, a specific ratio of r/S.

0 · Reply

Chrissytina Aug. 1 at 7:53 PM

$VERU I voted…no!!! Lfg 👍🏻

1 · Reply

PennyConnection1 Aug. 1 at 7:47 PM

$VERU green?

0 · Reply

TheRealTom Aug. 1 at 7:38 PM

$VERU The Shorts will lose this game...

0 · Reply

NolAsrtormZ Aug. 1 at 7:24 PM

$VERU LETS GO CLOSE HIGH OF DAY CHOO, CHOO,

0 · Reply

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Jun 11, 2025, 8:30 AM EDT - 7 weeks ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

May 28, 2025, 12:11 PM EDT - 2 months ago

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

May 28, 2025, 6:30 AM EDT - 2 months ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 26, 2025, 9:36 PM EDT - 2 months ago

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 8, 2025, 12:42 PM EDT - 3 months ago

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025, 9:30 AM EDT - 3 months ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:25 AM EDT - 3 months ago

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 6:30 AM EDT - 3 months ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 1, 2025, 8:30 AM EDT - 3 months ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Apr 16, 2025, 8:30 AM EDT - 3 months ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Mar 31, 2025, 8:30 AM EDT - 4 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Feb 19, 2025, 10:41 AM EST - 5 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 13, 2025, 2:35 PM EST - 6 months ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 6:30 AM EST - 6 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Jan 27, 2025, 10:34 AM EST - 6 months ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 6:30 AM EST - 6 months ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Dec 31, 2024, 8:30 AM EST - 7 months ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Nov 26, 2024, 8:30 AM EST - 8 months ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 5, 2024, 8:30 AM EST - 9 months ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Oct 21, 2024, 8:30 AM EDT - 10 months ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 16, 2024, 8:30 AM EDT - 10 months ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Sep 11, 2024, 8:30 AM EDT - 11 months ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Aug 10, 2024, 8:39 AM EDT - 1 year ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 17, 2024, 4:45 PM EDT - 1 year ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Steven B. Heymsfield M.D.

May 14, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the GLP-1 Based Therapeutics Summit

May 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Veru Reschedules Annual Meeting of Shareholders

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Feb 27, 2024, 7:15 PM EST - 1 year ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 20, 2024, 8:30 AM EST - 1 year ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 8, 2024, 1:36 PM EST - 1 year ago

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

Feb 8, 2024, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Feb 6, 2024, 8:30 AM EST - 1 year ago

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Jan 31, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 8:30 AM EST - 1 year ago

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Jan 8, 2024, 8:30 AM EST - 1 year ago

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

mrkymrk Aug. 2 at 2:03 PM

$VERU He is quite the Specker isn’t he?!

0 · Reply

NolAsrtormZ Aug. 2 at 1:20 PM

$VERU 5 business days for an 8k

0 · Reply

NolAsrtormZ Aug. 2 at 1:16 PM

$VERU they inform about a conference in November which is months AWAY But Wont inform investors of reverse split date and exact ratio which is Due in business days. Their priorities sheeeesh

0 · Reply

Woundntyouliketoknow Aug. 2 at 10:41 AM

$VERU Conference: Obesity, Metabolism & Weight Management Nov 19, 20 https://www.obesityconferences.com/speaker-details.php?speaker=3818#

1 · Reply

Eesnimi Aug. 2 at 3:45 AM

$VERU 1000% is not enough anymore to arrive to normality. Needs +1100%

0 · Reply

NolAsrtormZ Aug. 2 at 2:16 AM

$VERU NO 8k today. 5 business days until they must tell nasdaq a specific date, a specific ratio of r/S.

0 · Reply

Chrissytina Aug. 1 at 7:53 PM

$VERU I voted…no!!! Lfg 👍🏻

1 · Reply

PennyConnection1 Aug. 1 at 7:47 PM

$VERU green?

0 · Reply

TheRealTom Aug. 1 at 7:38 PM

$VERU The Shorts will lose this game...

0 · Reply

NolAsrtormZ Aug. 1 at 7:24 PM

$VERU LETS GO CLOSE HIGH OF DAY CHOO, CHOO,

0 · Reply

NolAsrtormZ Aug. 1 at 6:17 PM

$VERU Lol, few more cents 2 go to make a new 52 week low🤣🤣🤣

0 · Reply

NolAsrtormZ Aug. 1 at 5:22 PM

$VERU 6 business days to get to $1.00 $1.00 for 10 days needs to start by August 11

0 · Reply

NolAsrtormZ Aug. 1 at 5:21 PM

$VERU No 8k specifying r/s date🤣 6 business days to follow the nasdaq rules

0 · Reply

NolAsrtormZ Aug. 1 at 4:20 PM

$VERU these investors r diving head 1st into the r/S ...over 150,000 shares just to get cut into /20 🤣🤣

0 · Reply

Bearssuckbutt Aug. 1 at 3:48 PM

$MIST some wait for lower price, some wait the news to chase, smart investors are accumulating! gods speed to $15 come dec!!! best in class PVST, Afib treatment! A drug that will make the biggest difference in Health! $MRNA $VERU $NVAX dont sleep on this!!

1 · Reply

Woundntyouliketoknow Aug. 1 at 3:41 PM

$VERU 3rd QTR Results 2021 - August 12 - With a conference call 2022 - August 11 - With a conference call 2023 - August 10 - With a conference call 2024 - August 8 - With a conference call 2025 - ??? - Will there be a conference call ??? 2021 https://ir.verupharma.com/news-events/press-releases/detail/39/veru-to-report-fiscal-2021-third-quarter-financial-results 2022 https://ir.verupharma.com/news-events/press-releases/detail/153/veru-reports-third-quarter-fiscal-2022-financial-results 2023 https://ir.verupharma.com/news-events/press-releases/detail/184/veru-reports-fiscal-2023-third-quarter-financial-results 2024 https://ir.verupharma.com/news-events/press-releases/detail/217/veru-to-report-fiscal-2024-third-quarter-financial-results

0 · Reply

mrkymrk Aug. 1 at 2:46 PM

$VERU well officially no business update call next week.

0 · Reply

PennyConnection1 Aug. 1 at 1:39 PM

$VERU another trading week coming to a close and another week with Steiner at the helm…. Can’t get any boring that this

0 · Reply

NolAsrtormZ Aug. 1 at 2:53 AM

$VERU Will Steiner and team mess up and turn this into..... VERUQ?

0 · Reply

Scrapps64 Aug. 1 at 1:31 AM

$VERU Another lame reverse split.

1 · Reply

NolAsrtormZ Jul. 31 at 9:26 PM

$VERU Unless because they were in this mess since August 29 2024, they were grandfathered in with the OLD RULES

0 · Reply

NolAsrtormZ Jul. 31 at 9:20 PM

$VERU Why does this read as if they plan on being listed during the appeal process???? As if they got approved or didnot know new rules

1 · Reply

Market Cap	71.05M
Revenue (ttm)	16.89M
Net Income (ttm)	-37.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.80%
Debt to Equity Ratio	0.00

Volume	1,011,300
Avg Vol	2,981,348
Day's Range	N/A - N/A
Shares Out	146.58M
Stochastic %K	15%
Beta	-0.75
Analysts	Strong Sell
Price Target	$2.80